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Human Rights are the pioneer of all rights and it has been neglected until the establishment of the United Nations (UN) 
in 1945. The United Nations have recognized the Right to Health in various international conventions, including the right to 
access essential medicines as a human right, but still many people living in developing countries are denied access to 
essential medicines due to the heavy cost of patented medicines. In  the year 2000, the UN Committee on Economic, Social 
and Cultural Rights (CESCR) adopted General Comment No.14 to define Article 12 of the International Convention on 
Economic Social and Cultural Rights (ICESCR), it provides that four essential components are very important for access to 
medicine i.e. availability, accessibility, acceptability, and quality. On the other hand, the developed nations are using the 
provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) provisions as per their 
advantage which in turn affects human rights in developing countries like, India. There is a debate between the Right to 
Health and the patent regime in India. In the light of the above statements, the author tries to examine the existing issues and 
challenges with respect to the interface between human rights and intellectual property rights with special reference to 
protections of Right to Health and pharmaceutical patents.  
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The Patents Act, 1970 begins with the object to 
consolidate the laws relating to patents in India. It is 
to protect the interest of inventors. The rights of 
patent holders are protected through the registration of 
a patent in the patent office.  Presently, the Indian 
Patents Act, 1970 is known for both process and 
product patents.  In India, pharmaceutical companies 
and individuals do their registration under the Patents 
Act to protect their pharmaceutical products. The 
Patents Act, 1970 has been amended many times, and 
the Patents (Amendment) Act, 2005 is considered a 
landmark amendment because it allows product 
patents in India. This amendment has started a debate 
in the field of the right to health and the patent regime 
in India.
1
 India was the top exporters of generic 
medicine before 2005, also it has almost 60,000 
generic brands and 60 therapeutic categories in the 
market but which has declined after 2005.
2
 Mostly, 
the success of generic manufactures was possible due 
to the non-availability of the product patent in India.  
However, after the amendment of 2005, India has 
granted product patents in pharmaceutical products 
and which has reduced the production of generic 
medicines due to lack of technology transfer and fear 
of trade sanctions on the generic manufacturer.
3
 It is one 
of the reasons for the decline in generic medicine in 
India. The new process of manufacturing drugs 
without an altruistic approach is creating a hurdle in 
productions of generic medicines. The generic 
products industry is having certain restrictions of 
non-infringing patents because the patent holder holds 
patents even after the product patent expires. 
Whereas, the interface between human rights and 
intellectual property rights is a peculiar area which 
has emerged for the protection of right to health of an 
individual. Therefore, there is a conflict of interest 
between human rights and intellectual property rights. 
The reason is that of the individual-oriented rights of 
IPR whereas human rights are known for collective 
rights and individual rights. Hence, it is required to 
study the relationship between these two rights. 
Although, the right to health has found a place in 
the United Nations Declaration of Human Rights 
1948, it has not been the subject of academic debate 
concerning intellectual property rights a long time. In 
India, there are problems for primary necessities as 
most of the population is below the poverty line. 
Access to basic necessary medicines related to cancer, 
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tuberculosis, HIV/AIDS, etc are not also affordable.
4 
According to Indian Medical Association Report 
2016, 14 lakh people are suffering from cancer and it 
is increasing every year in numbers hence there is a 
need to look into with a sequitur.
5
 
There is a struggle for basic medicines with mostly 
proliferating diseases year by year due to which their 
right to health is violated. The rights to health, the 
right to access basic medicine, etc., are considered as 
human rights involved in Intellectual Property Rights.  
The right to health is also considered as a fundamental 
right under the right to life in the Constitution of 
India.
6
  Because of this, human rights and patent laws 
concerning compulsory licenses(CL) are required to 
be studied for a better understanding of the concept of 
human rights in Intellectual Property Rights and also 
the issues and challenges involved in it. The 
development of the concept of human rights in IPR is 
linked with international conventions. For this 
purpose, it is necessary to understand the various legal 
frameworks available at the national and international 
levels for the right to health and intellectual property 
rights.  
 
Intellectual Property Rights and Human Rights 
Intellectual property rights came into existence to 
serve the basic goal to protect the interest of 
intellectuals.  It simply envisages that the intellectuals 
who created the novelty should not only be 
recognized but also receives some monetary benefits 
out of their work. Sometimes, it is also labeled as a 
negative right that prevents others from stepping 
against the already created work. On the other hand, 
human rights are natural rights and to which every 
human being is entitled to enjoy right by birth. 
Human rights are also those fundamental rights which 
are inalienable and essential for every human being. 
In addition to this, Indian law defines human rights 
under Section 2(d) of the Protection of Human Rights 
Act, 1993, as right relating to life, liberty, equality, 
and dignity of an individual recognized by the 
constitution and international covenants and 
enforceable into the court of law.
7
 However, in the 
past several years the impacts of intellectual property 
rights on basic human rights have come under 
scrutiny. There are different kinds of links between 
human rights and intellectual property right like 
patent laws recognize the socio-economic dimensions 
to the patent rights and to that is the interest of patent 
holders and the interest of society.
8
 It has been 
discussed in the World Trade Organisation (WTO) 
Ministerial Conference in 2001 that the link between 
the human right to health and pharmaceutical patents 
has wider importance at the international level.
9
 In 
India, the impact of pharmaceutical patents on the 
right to health can be understood from several 
examples. For instance, every year 69,000 people die 
due to HIV/AIDS and 2.1. Million people are 
suffering from HIV/AIDS until 2017.
10
 Although, the 
Government of India has released the 2013 drug price 
control order and it has worked through the National 
Pharmaceutical Pricing Authority (NPPA) to control 
the high prices of medicines in India.
11
 In the last 20 
years, prices of medicines have changed due to the 
want of patent holders to maximize profit in return for 
their investments.
12 
Moreover, the cost of a patented 
drug for HIV is enormous. One month's dose of 
Atripla which is an anti-HIV drug costs US $ 1,300 
per month. Such a huge amount is not affordable to 
necessitous population living in developing countries 
claiming maximum lives.
13
 The lack of access to life-
saving drugs takes away the lives of the poor people 
living in third world countries and they are the most 
affected ones.
14 
In 2018, the Indian economy was 
considered as the seventh-largest economy in the 
world by nominal Gross Domestic Product (GDP) 
with the third-largest in purchasing power parity 
(PPP) terms.
15
 According to the 2017 Report of the 
WHO and World Bank, it was noticed that more than 
half of the world’s population and more than 7.3 
billion people do not have access to essential 
medicines and health services.
16
  In India,  most of the 
population is not able to spend money on health care 
including women, and other vulnerable groups are 
mostly affected due to poverty and social hierarchy.
17
 
Interestingly, India has never spent more than  
2 percent of its GDP on healthcare and healthcare 
facilities.
18 
Therefore, there is a need for a detailed 
discussion of these particular aspects of the right to 
health and intellectual property rights.  
 
Evolution of Intellectual Property Rights and 
Right to Health: International Scenario 
Although, the international right to health has been 
introduced in the United Nations in 1945, it was not 
noticed by the international community until 1978 and 
therefore not come up for academic discussions. It 
was the first Director-General of the World Health 
Organization who was a strong supporter of the right 
to health and due to his leadership, the right to health 
was firmly established in the International Bill of 
rights.
19
 Further, WHO started the programme ‘Health 




for All’ in the 1970s according to the right to health 
standards (World Health Assembly 1977). Therefore, 
this perspective is reflected in the Alma-Ata 
Declaration of 1978 underlying the importance  
of primary healthcare.
20
 In 1985, the University of 
Sherbrooke, Quebec hosted an event on right to 
health.  Thereafter, American Health Organization 
published a voluminous study on the Right to Health 
in America.
21
 It was mainly focused on comparative 
examinations of constitutions and international law to 
give a response to the Alma-Ata conference of 1978 
which affirms health as “a fundamental human right.”  
During 1992-1993, the American Association for the 
advancement of Science held a conference on ‘the 
right to health care’ which contributed to Audrey 
Chapman’s work on exploring a Human Rights 
Approach to Health Care Reforms.
22
  In 1993, there 
were two significant meetings held on the right to 
health. The first was held in September 1993 at 
Harvard Law School and the second in December 
1993 by the United Nations Committee on Economic, 
Social, and Cultural Rights for general discussion on 
right to health and attributed to the meaning of Article 




The role of the World Health Organization in 
propounding the right to health is remarkable and 
therefore in 1978 World Health Organisation (WHO) 
called the Alma Ata Conference in Kazhakisthan for 
declaration of the right to health. Further, Article 12 
of the International Covenant on Economic Social and 
Cultural Rights, (ICESCR) 1966, provides that “the 
States parties to the present Covenant recognize the 
right of everyone to the enjoyment of the highest 
attainable standard of physical and mental health”.
24
 
In 2000, the UN Committee on Economic, Social and 
Cultural Rights (CESCR) adopted General Comment 
No.14 in an attempt to define Article 12 of the 
ICESCR, which provides that four essential 
components are very important for access to medicine 
i.e. availability, accessibility, acceptability, and 
quality.
25
 The International Covenant on Economic, 
Social and Cultural Rights, 1966, (the ICESCR, 1966) 
under Article 15 (1)(c) provides that  States Parties 
who have ratified and acceded to this instrument, 
“recognize the right of everyone to enjoy the benefits 
of scientific progress and its applications”.
26
 Apart 
from this Article 25 of the Universal Declaration of 
Human Rights, 1948 also provides for the right to 
health as one of the components of human rights. 
Further that, Article 27of the UDHR, 1948 is a key 
player in the relationship between human rights and 
IPR. It provides that “everyone has the right to freely 
participated in the cultural right of the community 
and it gives the right to enjoy the share of scientific 
development”.
27
 Further interprets that it is for the 
protection of moral and material interest coming from 
scientific, literary, and artistic work created by the 
author. Therefore, it indicates that the monopoly 
rights of the author in case of intellectual property 
rights are subject to the enjoyment of others. 
Thereafter, in 2005 the General Comment No. 
17(2005), of the ICESCR, 1966, clearly mentioned 
that it is the right of everyone to enjoy and share the 
benefits of scientific developments. It also fixed the 
responsibility of participant countries to ensure that 
everyone should enjoy the benefit of scientific 
development and its applications. Because of this, all 
the benefits coming from Intellectual Property Rights 
must be available to all and everyone has an equal 
share in the scientific progress and its applications.  
It is said that human rights and intellectual property 
rights being treated separately and isolated but today, 
they are becoming intimate bedfellows.
28
 After World 
War II,Human Rights Communities were busy in 
codifying Human Rights laws and norms. Whereas, 
IPR organizations, since the incorporation of the Paris 
Convention, 1883, and Berne convention, 1886, and 
TRIPS, were busy in trade and commerce and has no 
direct connection with human rights. However, it was 
the human rights community that first took notice of 
the human rights approach in IPR. The First Event 
was related to the neglected rights of indigenous 
peoples because it has been found that multinational 
companies through patents, copyrights, and plant 
breeder’s rights lead to exploit indigenous people's 
rights. The Second Event was related to the consequence 
of linking intellectual property and trade through the 
TRIPS Agreement. It was related to a conflicting 
interest of TRIPS and Human Rights because 
noncompliance of TRIPS for least developed and 
developing countries can be the WTO threat of trade 
sanctions. The UN Human Rights system turned its 
attention to TRIPS in 2000.
29
 The United Nations 
took initiative by Special Rapporteur and Draft 
Declaration on the Rights of Indigenous Peoples  
in 1994 that started the protection of traditional 
knowledge and indigenous people. Another report of 
WIPO and High Commissioner for Human rights in 
1998 has been one of the most important events which 




discussed IPR and human rights in detail and it has 
provided a right to health, right to medicine as an 
integral part of human rights in IPR.
30
 The United 
Nations Sub-commission on Protection and Promotion 
of Human Rights, 2000/7 has been set up to see all 
these issues and stated that human rights must be 
given primacy over economic policies and agreement 
and also discussed public health and TRIPS.
31
 
The interface between intellectual property rights 
and human rights received the attention of the world 
due to criticism by several human rights groups. With 
the increasing demand for access to medicines, the 
right to health has emerged as the major ground for 
social interest instead of individual interest in the 
developing countries.  The debate is on the conflict 
between intellectual property rights which empower 
the individual with the fruits of growth and 
development. On the other hand, human rights confer 
equal status and rights on the part of everyone without 
any discrimination. Although, the Doha Ministerial 
Conference Declaration on TRIPS Agreement and 
Public health, 2001, recognized the importance of 
public health and intellectual property rights protection 
but still there is scope for its implementation in 
various countries.
32
 Because of the individual greed 
for patents, it has given the scope for experimentation 
at various levels and created a fight between human 
rights and intellectual property laws.  However, there 
are instances in which the Supreme Court of India in 
Novartis v Union of India AIR 2013 SC 1311 has 
given importance to the lifesaving drugs instead of 
Patent rights.
33
 In this case, the Novartis Pharmaceutical 
Company challenged the constitutional validity of 
Section 3 (d) of the Patent Act, 1970 for a patent over 
a cancer drug. It was related to the substance 
imatinibmesylate used for a cancer drug.  The Supreme 
Court of India held that imatinibmesylate is not 
patentable as it fails the test of Section 3(d) of the 
Patent Act, since it provides that mere discovery of a 
new form of a known substance does not result in 
innovation. Section 3(d) has been interpreted in detail 
and held that it was constitutionally valid. This 
interpretation has given a new approach to patent and 
lifesaving drugs. In this case, it was observed that it is 
no longer acceptable to the global public that 
hundreds of millions of people have been denied 
access to lifesaving medicines only because of the 
monopoly of pharmaceutical companies.  In another 
case of Roche v Cipla MIPR 2008 (2) 35,the patent 
holder Roche was denied an injunction before the 
Kerala High Court because of public interest and 
lifesaving drug in question.
34
 The High Court held 
that access to lifesaving drugs is more important than 
granting an injunction to pharmaceutical companies. 
The present discourse of the right to health and 
patents shows that developing countries are facing 
problems in access to medicines and the judiciary has 
the least role to protect the interest of society. The 
giant pharmaceutical companies from the developed 
world are major stakeholders.  Therefore, the social, 
economic, and political backwardness of developing 
and least developing countries are responsible for the 
conflict between intellectual property rights and 
human rights. 
 
Right to Health and Patent Regime in India 
In India, the right to health and the patent regime 
has developed drastically and both have significance 
under the constitution of India and other legislations. 
The constitution of India guarantees everyone’s right 
to the highest attainable standard of physical and 
mental health. In the case of the State of Punjab 
vMohinder Singh Chawla (1997) 2 SCC 83, it was 
held by the Supreme Court that the right to health is 
an integral part of the right to life, and the government 
should provide the basic healthcare facilities.
35
 In 
Hoffmann-La Roche Ltd. v Cipla Ltd., MIPR 2008 (2) 
35, the Delhi High Court refused to grant an 
injunction to Roche against Cipla for the production 
of patented drugs.
36
 In the present case, a right to 
health perspective can be seen by referring Article  
21 of the Constitution of India where the court 
considering the balance of convenience in a case 
where a pharmaceutical company was trying to obtain 
an injunction to prohibit the production of cheaper 
generic drugs.  Article 21 of the Indian Constitution, 
which provides for the right to life and which forms 
the bedrock of the right to health in India. The 
Supreme Court of  India in the case of C.E.S.C. Ltd. 
Etc v Subhash Chandra Bose and Ors AIR 1992 SC 
573, held that right to health is a fundamental right 
under Article 21 of the constitution of India.
37
 
Further, even if the right to health is considered as 
a fundamental right in every democratic country, it 
has not been implemented properly therefore there are 
various reports of WHO and WTO where it has 
shown that how developing and least developing 
countries are poor in the implementation of the right 
to health policies. According to the WHO estimates 
that one-third of the world’s population including the 
poorest South African and Asian countries are not 
having access to essential medicines.
38
 There are 




many reasons for not having access to medicines like 
poverty, poor health infrastructure, high prices of 
medicines, etc. One of the reasons is that patent 
protection is given to the pharmaceutical company 
and therefore the generic medicines could be a 
solution through compulsory licenses and voluntary 
license provisions under the patent laws. Otherwise, 
pharmaceutical firms can only produce the patented 
drugs which lead to the renunciation of affording 
newly invented drugs due to high prices. The primary 
object of pharmaceutical companies is to gain profit 
and therefore they opposed the compulsory licenses.  
The important contention of the pharmaceutical 
companies is that compulsory licenses will kill 
innovation and discourage Research and Development 
(R&D). However, the fact remains that compulsory 
licensing is the remedy to curb the abuse of exclusive 
protection of patents.
39
 The provision relating to the 
compulsory licenses is provided under Sections 84 to 
92 of the Patents Act 1970. The object of the 
compulsory license is to give authority to a third party 
by the government to work on the already patented 
subject matter. Therefore, the compulsory license 
could be a tool to protect public health at large in case 
of certain conditions and it could be helpful to reduce 
the cost of patented medicines.
40
 The TRIPS 
Agreement is under Article 31 provides compulsory 
licensing and certain flexibilities are given to grant a 
compulsory license in an emergency. The role of the 
Doha Declaration in 2001 is a turning point in public 
health and TRIPS.  Paragraph 5(b) and 6 of the Doha 
Declaration also provides for compulsory lessening 
which was the basis for the protection of public health 
in case of emergency and against the monopoly of 
pharmaceutical companies in case of patented 
medicines. Therefore, the compulsory license has 
been considered as a tool of government to fight 
against the monopoly of pharmaceutical companies. 
However, the developing countries lacking in granting 
the compulsory license and using the TRIPS 
flexibilities due to the fear of trade sanctions imposed 
by developed nations.
41
 The Patents Act, 1970 grants 
patent for 20 years and it gives protection to 
pharmaceutical companies for their patented drugs. 
Whereas, the provision of compulsory license given 
under Section 84 grants compulsory license after three 
years of patent grant that the government can allow 
anyone to research a particular patent on certain 
grounds without the consent of patentee in an already 
patented subject matter.  The three grounds must be 
fulfilled to get compulsory license i.e. a) reasonable 
requirement of the public concerning the patented 
invention have not satisfied b) the patented invention 
is not available to the public at a reasonably 
affordable price c) the patented invention is not 
worked in the territory of India. In the history of the 
Indian Patent laws, only one compulsory license has 
been granted and two were rejected.
42
 The reason for 
granting the first compulsory license was very 
interesting and has legal standing in India.In the first 
case of Bayer Corporation v Union of India and 
others, AIR 2014 Bom 178 the compulsory license 
has been granted to NATCO Pharma Ltd., a generic 
drug manufacturer to produce and sell Nexavar. In the 
present case, the judiciary made it clear that the public 
interest is of prime importance and India will not 
tolerate the exploitation of its masses by drug giants.
43
 
The other two applications for a compulsory license 
were filed by the BDR pharmaceutical in March 2013 
and LEE Pharmaceutical Ltd., 29 June 2015 to the 
controller of patents. However, both these applications 
were rejected on the ground that they do not fulfill the 




The right to health is considered a fundamental 
right under Article 21 of the Constitution of India. 
Apart from this Directive Principles of State Policy 
under Article 39 of the Constitution of India provides 
that the state shall provide adequate means of 
livelihood and ownership and control of material 
resources for common good. Article 47 provides the 
responsibility of the State to raise the level of 
nutrition and standard of living and to improve public 
health. The State has to provide basic health facilities 
and medicines to poor people. Therefore, to fulfill the 
above obligation Government of India through the 
Ministry of Health and Family Welfare through its 
various schemes like National Health Mission (NHM), 
Mission Indradhanushya, Affordable Medicines, and 
Reliable Implant for Treatment, Pradhan Mantri 
Swastya Suraksha Yojana (PMSSY), Ayushaman 
Bharat, and Pradhan Mantri Jan ArogyaYojana (AB-
PMJAY), etc., tries to provide medicines to people 
who are suffering from tuberculosis, HIV/AIDS, 
cancer, and various other diseases.
45 
However, it can 
be possible only when medicines are available at low 
cost and grants of compulsory license by the 
government to patented medicines for producing more 
generic medicines in public health. In India the 
situation is different, only one compulsory license has 




been granted and costly medicines relating to cancer, 
HIV/AIDS, and tuberculosis are beyond the reach of 
poor people. In addition to that, India is the signatory 
country to the Universal Declaration of Human 
Rights, 1948, and International Covenant on Economic 
Social and Cultural Rights, 1966, and other 
international instruments. The above international 
instruments have recognized the human rights 
approach in IPR for public health, right to life, right to 
access medicine, right to health, etc. Therefore, the 
Government of India must implement the agreements 
of these conventions with requisite seriousness and 
stringent actions.  
 
From TRIPS, 1994 to Doha Declaration, 2001 and 
TRIPS-plus  
The Agreement on the Trade-Related Aspects of the 
Intellectual Property rights 1994 has changed the world 
of intellectual property rights protection in India. It has 
come into force on 1January 1995. The significance of 
this agreement that it has given targets and transition 
periods to the member countries to implements its 
provisions as per their convenience. In the field of 
patents and human rights Articles 27 to 34 are directly 
related to its implementation.
46
 Article 31 provides for 
the compulsory licensing in the patents and gives the 
flexibility to implement it. According to Article 31 of 
the TRIPS Agreement, a patent can be used by the 
government or third parties authorized by the 
government to use a patent without the authorization of 
the patentee. It is granted on certain grounds and the 
first effort to obtain a license from patentee and other 
conditions is like an extreme emergency. Article 8 of 
TRIPS  provides for public health and it imposes an 
obligation on member states in formulating laws 
relating to patents they must give importance to public 
health.
47
 Therefore, considering the need for the  
right to health the World Trade Organization in its 
Ministerial Conference held at Doha discussed the 
TRIPS and public health in 2001.  The Doha 
Declaration, 2001 in Paragraph 4, 5(b) and 6 have great 
importance since it provides compulsory license 
provisions. Paragraph 5(b) of the Doha Declaration 
provides that the right to issue the compulsory license 
depends on the country that wants to grant it. Paragraph 
6 of the Doha Declaration, 2001 was very much 
debatable in the field of right to health and patents.
48
 
The role of the United States and other developed 
countries opposed compulsory license and they argued 
that granting compulsory licensing should be limited to 
the most severe public health problems and the  
needy nations.
49
  However, the developing countries 
(especially, India and Brazil) opposed the US and other 
developed countries to provide basic medicines to the 
needy and poor people of the developing Country. 
After all deliberations Paragraph 6 provides that WTO 
member countries lacking in manufacturing capacities 
in pharmaceuticals can make effective use of the 
compulsory license for public health.
50
 Further, the 
Doha Declaration recognizes various flexibilities in 
Paragraph 4 which provides that public health rights 
prevail over individual intellectual property rights.
51 
After this, Doha Declaration and TRIPS provisions 
right to health and public health come to light but to 
bypass these provisions new agendas were set by the 
developed countries through bilateral and multilateral 
agreements between countries. The TRIPS-plus is one 
of the forms of it and it provides that minimum 
standard protection commitment by WTO members 
has to follow in implementing TRIPS provisions. 
Therefore, in brief, it can be said that pharmaceutical 
companies have a big budget for research and 
development. They spend huge money on patented 
drugs and after getting product patent they will have 
exclusive licenses for production and marketing and 
hence they increase the price of the patented drugs.
52
  
It includes the cost of research and development and 
the profits are shared among shareholders, in this way 
the pharmaceutical companies do the business.
53
 
Pharmaceutical companies base their claim largely on 
two grounds. Firstly, that they have spent money on 
research and development of the invention and one can 
make a profit from these patents for a limited period  
of 20 years, therefore, many multinational companies 
work for a profit. And if compulsory licenses are 
granted to patented medicines then it would discourage 
them to work without profit in return.  
Secondly, those competitors can produce the same 
drug through reverse engineering and it would 
discourage innovation and research in the field of 
science and technology.
54
 Therefore, both the 
arguments of the right to health and patents are 
important. However, the fact is that due to the high 
prices of patented drugs many people could afford 
medicines and it restricts them to enjoy their 
fundamental right to health. 
 
Role of Developed Nations in Patents and its 
Impact on Right to Health in India 
There is no clear definition for developed and 
developing countries. However, the World Trade 
Organisation provides some criteria for developed  




and developing countries. In the field of patents and 
the right to health, the role of developed nations is 
decisive.The United Nations has accepted the 
accessibility of essential medicine is basic human 
rights to health in various international instruments.
55
 
The lack of access to essential medicine in a country 
is the result of many factors, but the primary reason is 
the prevalence of high prices of medicines and strong 
intellectual property protection. Although, the TRIPS 
Agreement lays down minimum standards for the 
protection of intellectual property and offers 
safeguards and flexibilities to prevent patent abuse  
but the developed countries like United States (US) 
and European Union (EU) by signing bilateral  
trade agreements usurp the flexibilities of TRIPS 
Agreement. The use of Free Trade Agreements, Anti-
Counterfeiting Trade Agreement, Trade Pacific 
Partnership Agreement and Transatlantic Trade and 
Investment Partnership Agreements by the United 
States affected the accessibility of essential medicines 
to the population in developing countries.
56
 It also 
coerces the developing countries to accept the 
stringent provisions of TRIPS-plus.
57
 The developed 
nations supported the pharmaceutical giants and 
demanded increased patent protection under strict 
intellectual property laws. They contended that an 
increase in the compulsory license will discourage 
their R&D.
58
 However, there is no link between 
compulsory license and decline in R& Dof the 
pharmaceutical product. In various instances, the US 
has established that developed countries can be 
hypocritical about their stand by using the threat of 
compulsory license in times of need.
59
 
The experiences of developing countries like South 
Africa, Thailand, and India are indicative of the 
difficulties faced by the other developing and least 
developed countries in implementing TRIPS flexibilities 
for making essential medicines available to their 
population at affordable prices.
60
 The Thailand 
government issued three compulsory licenses in 
Plavix for heart disease and Kaletra (Abbott) and 
Efavirenz (Merck) for a drug against AIDS on the 
ground that such licenses could benefit many people 
and their use would establish the example for other 
countries to use compulsory license for social 
welfare.
61
 The action of Thailand started a debate 
between developing and developed countries. The US 
issued a Special Report 301 Watch List against 
Thailand due to weakening respect for the patent. The 
US demanded the Thailand Government to cancel the 
compulsory license unless they confirm their scope  
in using them. This type of action of the US  
shows bypassing TRIPS flexibilities and accepting 
TRIPS-plus provisions to institute more stringent 
pharmaceutical IP protection and thereby preventing 
access to essential medicines to the population  
of developing countries.
62
 Therefore, there is a  
debate between compulsory license in patents and 
public health.  
The first issue to discuss is why there are fewer 
applications for compulsory licenses in India and 
which in turn affects the production of generic 
medicines and public health. The second issue is that 
how big pharmaceutical companies and developed 
nations have involvement in dealing with the 
compulsory license. Therefore, it is a matter of human 
rights because the inaccessibility of patented 
medicines is one of the aspects of the right to health. 
In the case of the first issue, the debate starts with the 
fewer number of compulsory license applications and 
which in turn affects the production of generic 
medicines and public health. In India, the right to 
health is considered a fundamental right under Article 
21 of the Constitution of India. However, people are 
struggling for basic medicines and their fundamental 
rights are being violated due to patented medicines. It 
is accepted that the provisions in TRIPS under Article 
31 and Section 84 of the Patents Act, 1970 are dealing 
with the compulsory license. The lacuna under Article 
31 is that it has given a wider scope to the concerned 
state parties to implement the compulsory license 
policies. However, after the WTO conference on 
Public health and TRIPS in 2001 warned about 
issuing a compulsory license in an emergency like 
public health. On the other hand, provision of Section 
84 is very clear about compulsory license and only 
one compulsory license is granted in India. There are 
many advantages of the compulsory license and one 
advantage is that it allows firms in developing 
countries to have foreign-owned inventions without 
the consent of the patent owner.
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 It gives the right to 
the third party to research in an already patented 
subject matter. However, pharmaceutical companies 
make their promises and threats to coax developing 
nations into strengthening patent protection and use 
developed country government for their self-interest.
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There are also serious problems with the capacity  
of government at the local level. Even most of the 
developing countries don’t have domestic manufacturing 
capacities and many governments lack the administrative 




resources to navigate even the relatively simple 
requirements of compulsory licensing.
65 
All these 
factors were responsible for the widespread prioritization 
of intellectual property protection over health-related 
rights. Therefore, as discussed above regarding 
compulsory license in India that only three cases of 
compulsory licensing have been filed and out of 
which only one is granted and the rest two were 
rejected. 
The first compulsory license was granted to Bayer 
Corporation and in the case of Bayer Corporation v 
Union of India, AIR 2014 Bom 178, the court held 
that Bayer failed to prove under Section 84 of the 
Patent Act, 1970 and therefore NATCO was allowed 
to produce generic medicines. This case was related to 
the Cancer medicine Naxavar produced by the Bayer 
Corporation which cost around Rs.2,80,000 per month 
whereas NATCO a generic drug manufactures in 
India claimed it give for a cheaper price. Initially, 
Natco applied for the Voluntary license in December 
2010 but Bayer did not respond, and therefore in 
2011, NATCO applied for a compulsory license to the 
Controller of Patents.Then Controller of Patents 
granted a compulsory license to NATCO to produce 
generic medicines.  
The second case is of BDR Pharmaceutical Private 
Ltd. v Bristol-Myers Squibb 2015(64) PTC 135 (Del)  
filed in March 2013. The BDR Pharmaceutical applied 
for a compulsory license to make generic medicine for 
anti-cancer drugs patented by Bristol-Myers Squibb in 
India. The Controller General of Patents has rejected the 
BDR pharmaceutical application of compulsory  
license for Bristol-Myers Squibb’s (BMS) cancer  
drug SPRYCEL. SPRYCEL is a brand name of the 
medicine with the active pharmaceutical ingredient of 
DASATINIB. This medicine was used by patients with 
Chronic Myeloid Leukemia.  In the present case, BDR 
first requested a voluntary license on 2February 2012, 
for manufacturing DASATINIB in India. The Bristol-
Myers Squibb’s (BMS) reply to voluntary license is 
negative and therefore BDR treated it as a rejection of 
voluntary license. Further, BDR requested compulsory 
license of DASATNIB on 4 March 2013, and it claimed 
that DASATINIB is a suitable chemotherapeutic option 
for the treatment of cancer and Chronic Myeloid 
Leukemia. BDR also submitted that the price of each 
tablet sold by the BMS is Rs. 2761/- which will cost 
Rs.1,65,680/- tablets per month. Therefore, BDR 
claimed that they will provide this drug to the public at a 
proposed price of Rs.135/- per tablet which will cost 
around Rs.8100/- per month for the treatment of Chronic 
Myeloid Leukemia patients. It will be available to cancer 
patients at a low cost and therefore compulsory license 
has to be granted. The Controller of Patent rejected the 
application on the ground that BDR has failed to make 
out the prima facie case for making of an order under 
Section 87 of the Patents Act, 1970. It also pointed out 
that BDR before applying for a compulsory license the 
applicant didn't try to convince the patentee for 
voluntary license and out-rightly rejected an application 
for the grant of compulsory license.  
The third case is of LEE Pharmaceutical Private 
Ltd., v AstraZeneca, CLA No. 1 of 2015,    filed for 
compulsory license against one of the patented drugs 
of BMS in the name of drug Saxagliptin for treating 
Diabetes Mellitus. This drug was assigned to Astra 
Zeneca by way of Deed of Assignment and therefore 
it was sold and marketed by Astra Zeneca. Lee 
Pharmaceutical contended that this drug was not 
manufactured in India even after 8 years of the grant 
of a patent to BMS. Further, it was argued that the 
cost of the imported drug was around Rs.0.80/-per 
tablet but it was sold at Rs.41-45/- per tablet. 
Therefore, LEE Pharmaceutical submitted that they 
will make it available for the public at Rs.27/- per 
tablet. The Controller of Patent discussed in detail the 
grounds given under Section 84 of the Indian Patent 
Act, 1970, and finally rejected the application on the 
ground that the application does not fulfill any one of 
the grounds of Section 84 of the Patents Act, 1970. 
The second issue is that how big pharmaceutical 
companies and developed countries play a key role in 
patent and right to health. Therefore, to understand 
the nitty-gritty of compulsory license in the Patents 
Act and access to medicines the consequence of 
granting the first compulsory license in India is  
the eye-opener for the world. And India is not the 
only country that faced the difficulty of granting 
compulsory license but there are other countries like 
Brazil and Thailand which has the same history of 
Report 301 of the US Trade Act, 1974.
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 In India, 
after the grant of a compulsory license to NATCO, 
the USA issued Report 301 against India for granting 
the compulsory license on the ground that the Indian 
government is not complying with the provisions of 
TRIPS and WTO.
67
  Report 301 is a US provision of 
the Trade Act, 1974 which has many amendments. It 
is a weapon of the US government to ban and threaten 
the other countries for not cooperating in IPR matters 
of US Companies. 
According to Section 301 of Trade Act, 1974, 
United States Trade Representative issues an Annual 




Report in which those countries which could not 
protect the IPR of US companies are identified and 
threatened.
68
 Therefore, it was not a criticism of the 
US policies for trade sanctions because every country 
has its agenda for business and commerce. However, 
interestingly after the 10 years of Doha Declaration a 
policy brief prepared by South Centre to celebrate 10 
anniversary of WTO Doha Ministerial Conference it 
was pointed out that Multinational Pharmaceutical 
Companies and developed countries put pressure  
on the developing countries from using TRIPS 
flexibilities of public health on compulsory licenses.
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Because of the above, intellectual property rights and 
the right to health has a different object.  Intellectual 
Property Law has a provision of compulsory license 
to balance the need of the society therefore it cannot 
be said that intellectual property laws creating a 
hurdle for human rights. But the fact is that despite 
having provision of compulsory license with specific 
grounds and power is given to the government to 
implement it. The TRIPS provisions also provide 
flexibilities for a compulsory license like under 
Section 84 it grants compulsory license only after 
three years of patent.  Although the TRIPS provisions 
under Article 31 provides for public emergency and 
the locking period given under Section 84 of the 
Patents Act 1970 provides enough scope to the 
pharmaceutical companies to use patent.  Therefore, 
the argument of not giving credit to the patent holder 
for his work is untenable and it will not reduce 
innovation in the field of pharmaceutical products. It 
is pertinent to understand both the aspects of patents 
and human rights. Further, the experience of India and 
other developing countries can be easily understood 
by the following example.  The history of non-
cooperation of the United States to India in case of 
patented medicines and human rights to access to 
lifesaving medicines can be traced from the National 
Human Right Commission (NHRC) notice to the 
government of India on 1 April 2016. The National 
Human Rights Commission (NHRC) issued a notice 
on first April 2016 to the Government of India to 
submit a report that the government had given private 
confirmations to the United States that India would 
embrace a rigorous methodology when granting 
compulsory licenses over protected medications.
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While the Government of India, Ministry of 
Commerce and Industry in a Press Report in March 
2016, had denied such claims in response to the 
NHRC notice. Further, immediately after the Ministry 
of Commerce and Industry Press Release in 2016, Lee 
Pharma and BDR Pharma (the main two organizations 
to petition for compulsory licenses after NATCO) 
reported that they would not go in an appeal after 
rejection of application fora compulsory license by 
the Indian Patent Office.
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 This is how developed 
nations put pressure on developing nations and these 
are the issues involved in compulsory license and 
human rights. The above study shows that how the 
government is rejecting compulsory licenses which in 
turn affect the production of generic medicines and 
public health.
72
 It creates serious questions about the 
role of State as facilitator and mediator between the 
monopoly of the patent holder and public good. 
Therefore, such trends of policy shift of government 
from human rights perspectives to economic point of 
view are menacing to the welfare states. 
 
Conclusion 
The concept of the human rights approach in Patents 
and Public Health has been discussed at the Doha 
Declaration on TRIPS and Public health in 2001. The 
compliance of Article 31 of the TRIPS Agreement and 
Section 84 of the Patent Act is purely based on the 
policy decisions of the countries who decide the grounds 
of compulsory license. Whereas the right to access  
basic medicines is considered as human rights, and 
international conventions recognized these rights in IPR. 
However, there is a contradiction in the action of the 
international community and the political will of a 
developed country to issue a compulsory license in 
pharmaceutical products as it is evident from the Indian 
grant of compulsory license in Bayer's Case and the 
reaction of the US after a compulsory license.  The  
one incident of suo-motu action by the NHRC in  
2016 against the Government of India and reply to the 
NHRC by the Ministry of Commerce and Industry has 
indicated the involvement of the political will of big 
pharmaceutical companies and their link with developed 
countries. Therefore, it may be one of the reasons for 
less number of compulsory license applications in India 
and across the world.  
The above study shows that big pharmaceutical 
companies and developed countries (especially, the 
US and EU) have involvement in dealing with 
compulsory licenses and this creating obstacle in the 
dissemination of medicines to an individual which 
resultantly affect human rights. The economic 
expectation of pharmaceutical companies is higher in 
the patented products and therefore the prices of 
patented drugs are costly and beyond the reach of 
common people. Therefore, patent laws are responsible 




for the lack of accessibility of medicines. It can be 
concluded that the laws at the international and 
national levels dealing with compulsory license and 
human health rights are not adequate to enforce it 
strictly. However, the role of developed nations and 
particularly the United States is one of the dominant 
factors in deciding the compulsory licensesin 
developing countries and particularly in India.  
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